Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy

Antiviral Research

Volumn 96, Issue 3, 2012, Pages 422-429

  Mirandola, Silvia ^a   Sebastiani, Giada ^b   Rossi, Cristina ^c   Velo, Emanuela ^d   Erne, Elke Maria ^e   Vario, Alessandro ^f   Tempesta, Diego ^b   Romualdi, Chiara ^g   Campagnolo, Davide ^a,g   Alberti, Alfredo ^a,g  

^a VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^b OSPEDALE DELL'ANGELO   (Italy)

^c CA FONCELLO HOSPITAL   (Italy)

^d Cittadella Hospital   (Italy)

^e UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^f Department of Clinical Pathology   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

Author keywords

Chronic hepatitis B; HBV genotype; Nucleot(s)ide analogues therapy; YMDD mutations

Indexed keywords

ADEFOVIR; LAMIVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL;

ADENINE; ADMINISTRATION, ORAL; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENES, POL; GENOTYPE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MUTATION; MUTATION RATE; ORGANOPHOSPHONATES; PREVALENCE; VIRUS REPLICATION;

HEPATITIS B VIRUS; LETTUCE MOSAIC VIRUS;

EID: 84869230547     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.09.014     Document Type: Article

References (35)

1. Akarsu M., Sengonul A., Tankurt E., Sayiner A.A., Topalak O., Akpinar H., Abacioglu Y.H. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay. J. Gastroenterol. Hepatol. 2006, 21:1783-1788.
2. Amini-Bavil-Olyaee S., Hosseini S.Y., Sabahi F., Alavian S.M. Hepatitis B virus(HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine. Int. J. Infect. Dis. 2008, 12:83-87.
3. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. 1995, B57:289-300.
4. Cassino L., Benetti S., Fay F., Tanno H., Quarleri J. Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations. BMC Infect. Dis. 2011, 11:178.
5. Chu C.J., Keeffe E.B., Han S.H., Perrillo R.P., Min A.D., Soldevila-Pico C., Carey W., Brown R.S.Jr., Luketic V.A., Terrault N., Lok A.S., U.S.HBV Epidemiology Study Group Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003, 38:619-628.
6. Damerow H., Yuen L., Wiegand J., Walker C., Bock C.T., Locarnini S., Tillmann H.L. Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J. Med. Virol. 2010, 82:1850-1858.
7. Di Marco V., Marzano A., Lampertico P., Andreone P., Santantonio T., Almasio P.L., Rizzetto M., Craxi' A., Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004, 40:883-891.
8. European association for the study of the liver. 2012. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. (Mar 20).
9. Ghany M.G., Doo E.C. Antiviral resistance and hepatitis B therapy. Hepatology 2009, 49(Suppl. 5):S174-S184.
10. Günther S., Fischer L., Pult I., Sterneck M., Will H. Naturally occurring variants of hepatitis B virus. Adv. Virus Res. 1999, 52:25-137.
11. Guo J.J., Li Q.L., Shi X.F., Zhang D.Z., Zeng A.Z., Feng T., Huang A.L. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide naïve patient. Antiviral Res. 2009, 81:180-183.
12. Hadziyannis S.J., Papatheodoridis G.V., Dimou E., Laras A., Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e-antigen-negative chronic hepatitis B. Hepatology 2000, 32:847-851.
13. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., Marcellin P., Lim S.G., Goodman Z., Ma J., Brosgart C.L., Borroto-Esoda K., Arterburn S., Chuck S.L., Adefovir Dipivoxil 438 Study Group Long-term therapy with Adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743-1751.
14. Han Y., Huang L.H., Liu C.M., Yang S., Li J., Lin Z.M., Kong X.F., Yu de M., Zhang D.H., Jin G.D., Lu Z.M., Gong Q.M., Zhang X.X. Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naïve patients. J. Gastroenterol. Hepatol. 2009, 24:1417-1423.
15. Inoue J., Ueno Y., Wakui Y., Niitsuma H., Fukushima K., Yamagiwa Y., Shiina M., Kondo Y., Kakazu E., Tamai K., Obara N., Iwasaki T., Shimosegawa T. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. J. Viral. Hepat. 2011, 18:206-215.
16. Karatayli E., Karatayli S.C., Cinar K., Gokahmetoglu S., Güven K., Idilman R., Yurdaydin C., Bozdayi A.M. Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. J. Clin. Virol. 2012, 53:130-134.
17. Keeffe E.B., Dieterich D.T., Pawlotsky J.M., Benhamou Y. Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin. Gastroenterol. Hepatol. 2008, 6:268-274.
18. Kobashi H., Fujioka S., Kawaguchi M., Kumada H., Yokosuka O., Hayashi N., Suzuki K., Okanoue T., Sata M., Tsubouchi H., Sato C., Kiyosawa K., Tanikawa K., Seriu T., Ishikawa H., Takaki A., Iwasaki Y., Osawa T., Takaki T., Sakaguchi K., Shiratori Y., Yamamoto K., Tenney D.J., Omata M. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol. Int. 2009, 3:403-410.
19. Kobayashi M., Suzuki F., Akuta N., Suzuki Y., Arase Y., Ikeda K., Hosaka T., Sezaki H., Kobayashi M., Iwasaki S., Sato J., Watahiki S., Miyakawa Y., Kumada H. Response to long term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C. J. Med. Virol. 2006, 78:1276-1283.
20. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., Tanwandee T., Tao Q.M., Shue K., Keene O.N., Dixon J.S., Gray D.F., Sabbat J. Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004, 351:1521-1531.
21. Liu B.M., Li T., Xu J., Li X.G., Dong J.P., Yan P., Yang J.X., Yan L., Gao Z.Y., Li W.P., Sun X.W., Wang Y.H., Jiao X.J., Hou C.S., Zhuang H. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients. Antiviral Res. 2010, 85:512-519.
22. Lok A.S., Zoulim F., Locarnini S., Bartholomeusz A., Ghany M.G., Pawlotsky J.M., Liaw Y.F., Mizokami M., Kuiken C., Hepatitis B Virus Drug Resistance Working Group Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007, 46:254-265.
23. Margeridon-Thermet S., Shulman N.S., Ahmed A., Shahriar R., Liu T., Wang C., Holmes S.P., Babrzadeh F., Gharizadeh B., Hanczaruk B., Simen B.B., Egholm M., Shafer R.W. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI- naïve patients. J. Infect. Dis. 2009, 199:1275-1285.
24. McMahon B.J. The influence of hepatitis B virus genotype and subgenotype on thenatural history of chronic hepatitis B. Hepatol. Int. 2009, 3:334-342.
25. Mirandola S., Campagnolo D., Bortoletto G., Franceschini L., Marcolongo M., Alberti A. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. J. Viral. Hepat. 2011, 18:e212-e216.
26. Orito E., Fujiwara K., Tanaka Y., Yuen M.F., Lai C.L., Kato T., Sugauchi F., Kusakabe A., Sata M., Okanoue T., Niitsuma H., Sakugawa H., Hasegawa I., Mizokami M. A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Hepatol. Res. 2006, 35:127-134.
27. Papatheodoridis G.V., Dimou E., Laras A., Papadimitropoulos V., Hadziyannis S.J. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002, 36:219-226.
28. Pastor R., Habersetzer F., Fafi-Kremer S., Doffoel M., Baumert T.F., Gut J.P., Stoll-Keller F., Schvoerer E. Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-nai{dotless}ve patients. World J. Gastroenterol. 2009, 15:753-755.
29. Patterson S.J., George J., Strasser S.I., Lee A.U., Sievert W., Nicoll A.J., Desmond P.V., Roberts S.K., Locarnini S., Bowden S., Angus P.W. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011, 60:247-254.
30. Peters M.G., Hann H.wH., Martin P., Heathcote E.J., Buggisch P., Rubin R., Bourliere M., Kowdley K., Trepo C., Gray D.fD., Sullivan M., Kleber K., Ebrahimi R., Xiong S., Brosgart C.L. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004, 126:91-101.
31. Pollicino T., Isgrò G., Di Stefano R., Ferraro D., Maimone S., Brancatelli S., Squadrito G., Di Marco V., Craxì A., Raimondo G. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients. Antiviral Theor. 2009, 14:649-654.
32. Rhee S.Y., Margeridon-Thermet S., Nguyen M.H., Liu T.F., Kagan R.M., Beggel B., Verheyen J., Kaiser R., Shafer R.W. Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery. Antiviral Res. 2010, 88:269-275.
33. Ryu H.J., Lee J.M., Ahn S.H., Kim do Y., Lee M.H., Han K.H., Chon C.Y., Park J.Y. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J. Med. Virol. 2010, 82:1835-1842.
34. van Bömmel F., de Man R.A., Wedemeyer H., Deterding K., Petersen J., Buggisch P., Erhardt A., Hüppe D., Stein K., Trojan J., Sarrazin C., Böcher W.O., Spengler U., Wasmuth H.E., Reinders J.G., Möller B., Rhode P., Feucht H.H., Wiedenmann B., Berg T. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010, 51:73-80.
35. Zoulim F., Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009, 137:1593-1608.